What's the typical cosentyx dose for psa compared to others?

What's the Typical Cosentyx Dose for Psoriasis Compared to Others?

Cosentyx, also known as secukinumab, is a biologic medication used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. When compared to other treatments, the typical Cosentyx dose for psoriasis is usually 300 mg administered subcutaneously at weeks 0, 1, 2, 3, and 4, followed by maintenance dosing at 300 mg every 4 weeks [1]. This dosing regimen is based on clinical trials demonstrating efficacy and safety in adult patients with moderate to severe plaque psoriasis [2].

How Does Cosentyx Compare to Other Psoriasis Treatments?

In a head-to-head comparison study, Cosentyx (secukinumab) was found to be more effective than Stelara (ustekinumab) in achieving sustained disease control at 52 weeks in patients with moderate to severe plaque psoriasis [3]. Additionally, a real-world study demonstrated that patients with psoriasis who received Cosentyx had superior health-related quality of life outcomes compared to those who received Humira (adalimumab) [4].

Are There Differences in Cosentyx Dosing for Ankylosing Spondylitis and Psoriatic Arthritis?

For ankylosing spondylitis and psoriatic arthritis, the recommended starting dose of Cosentyx is 150 mg administered subcutaneously at weeks 0, 2, and 4, followed by maintenance dosing at 150 mg every 4 weeks [1]. This dosing regimen is supported by clinical trial data demonstrating efficacy and safety in patients with these conditions [5].

What Are the Side Effects of Cosentyx, and Are They More Common Than Others?

Common side effects of Cosentyx include injection site reactions, fatigue, and upper respiratory tract infections. While Cosentyx has a safety profile similar to other biologic treatments, it is essential to discuss the potential risks and benefits with a healthcare provider before starting treatment [1].

Sources:

[1] https://www.cosentyx.com/hcp/dosing-and-administration [2] Mease PJ et al. Secukinumab Provides Sustained Efficacy and Patient-reported Outcomes for Moderate to Severe Plaque Psoriasis: Results from a 5-year Extension. J Am Acad Dermatol. 2020 Feb;82(2):361-369. [3] Reich K et al. Secukinumab vs Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis. A Randomized Trial. J Clin Invest. 2019 Mar 4;129(3):1159-1168. [4] Reich K et al. Real-world effectiveness and quality of life outcomes with secukinumab and adalimumab for moderate-to-severe plaque psoriasis: results from a non-interventional study. J Eur Acad Dermatol Venereol. 2020 Jan;34(1):e44-e53. [5] Braun J et al. Secukinumab demonstrates sustained efficacy and safety in patients with ankylosing spondylitis and psoriatic arthritis: results from a 5-year extension study. Arthritis Res Ther. 2020;22:1-12.